Gilead Sciences Director Sells Over $2.6M in Stock

Gilead Sciences Director, Anthony Welters, reported significant trading activity on August 26, 2026. The transactions involved exercising stock options and subsequently selling the acquired shares.

• Option Exercise (Acquisition): Mr. Welters exercised options to acquire a total of 18,000 shares of common stock. The exercises were done in two tranches: 7,718 shares at $60.67 and 10,282 shares at $61.35, for a total acquisition cost of approximately $1.1 million.

• Stock Sale (Disposition): Concurrently, Mr. Welters sold 18,000 shares of common stock in four separate transactions at weighted average prices ranging from $148.23 to $148.82. The total proceeds from these sales amounted to approximately $2.68 million.

These trades were conducted under a pre-arranged Rule 10b5-1 trading plan, which was adopted on May 27, 2026. This type of plan allows insiders to set up a predetermined schedule for buying or selling stocks at a future date, providing an affirmative defense against accusations of trading on nonpublic information. After these transactions, Mr. Welters' direct holdings in Gilead Sciences stand at 12,894 shares.